Mesoblast (NASDAQ:MESO) Given a $16.00 Price Target by Oppenheimer Analysts

Mesoblast (NASDAQ:MESO) has been given a $16.00 target price by equities researchers at Oppenheimer in a research note issued to investors on Wednesday, December 20th. The brokerage presently has a “buy” rating on the stock. Oppenheimer’s price objective would suggest a potential upside of 183.69% from the stock’s current price. Oppenheimer also issued estimates for Mesoblast’s FY2020 earnings at $1.15 EPS and FY2021 earnings at $2.70 EPS.

Other equities research analysts also recently issued research reports about the company. Cantor Fitzgerald reiterated a “buy” rating on shares of Mesoblast in a research report on Wednesday, August 23rd. Maxim Group set a $14.00 target price on Mesoblast and gave the company a “buy” rating in a research note on Wednesday, August 30th. CIBC began coverage on Mesoblast in a research note on Thursday, August 31st. They issued an “outperform” rating and a $16.00 target price on the stock. Zacks Investment Research raised Mesoblast from a “hold” rating to a “buy” rating and set a $6.50 target price on the stock in a research note on Wednesday, October 4th. Finally, ValuEngine cut Mesoblast from a “hold” rating to a “sell” rating in a research note on Friday, September 15th. Three research analysts have rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $13.14.

Shares of Mesoblast (NASDAQ:MESO) opened at $5.64 on Wednesday. The stock has a market capitalization of $516.39, a price-to-earnings ratio of -6.88 and a beta of 2.44. Mesoblast has a 12-month low of $4.80 and a 12-month high of $12.50.

TRADEMARK VIOLATION NOTICE: “Mesoblast (NASDAQ:MESO) Given a $16.00 Price Target by Oppenheimer Analysts” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The original version of this report can be accessed at

About Mesoblast

Analyst Recommendations for Mesoblast (NASDAQ:MESO)

Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with's FREE daily email newsletter.

Leave a Reply